A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects
Condition: Healthy
Intervention: Ir-CPI - Dose 1; Ir-CPI - Dose 2; Ir-CPI - Dose 3; Ir-CPI - Dose 4; Placebo
Intervention description: 6 participants received a single intravenous dose of 1.5 mg/kg of Ir-CPI during 6 hours; 6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours; 6 participants received a single intravenous dose of 6.0 mg/kg of Ir-CPI during 6 hours; 6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours; For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Sequential Assignment
Masking: Double (Participant, Investigator)
Enrollment: 32.0
Sex: Male
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Antithrombotic; Intrinsic coagulation pathway

Summary:

      The purpose of this First-in-Human study is to assess the safety, tolerability,
      pharmacokinetics, and pharmacodynamics of Ir-CPI, a novel dual inhibitor of FXIIa and FXIa,
      following IV administration of single ascending doses in healthy male volunteers.
    

Eligibility criteria:

        Inclusion Criteria:

        Participants must satisfy all of the following inclusion criteria before being allowed to
        enter the study:

          1. Have given written informed consent approved by the relevant Ethics Committee (EC)
             governing the site, indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study.

          2. Male participants between 18 and 55 years of age, inclusive at screening.

          3. Otherwise healthy with no clinically significant abnormalities as determined by
             medical history, physical examination, blood chemistry assessments, haematological
             assessments, coagulation and urinalysis, measurement of vital signs, and ECG. Isolated
             out-of-range values judged by the PI (or designated physician) to be of no clinical
             significance can be allowed. This determination must be recorded in the participant's
             source documents.

          4. Have a body weight in the range of 50 to 90 kg inclusive at screening. Have a body
             mass index (BMI) of 19 to 28 kg/m2 inclusive at screening.

          5. Agree to abstain from alcohol intake 24 hours before administration of study drug,
             during the in-patient period of the study and 24 hours prior to all other ambulatory
             visits, up until and including the discharge visit.

          6. Agree not to use prescription medications within 14 days prior to study drug
             administration and through the duration of the study, unless approved by the PI and
             Sponsor medical monitor.

          7. Non-smokers or abstinence from tobacco or nicotine-containing products for at least 3
             months prior to screening.

          8. Agree not to use over-the-counter (OTC) medications [including decongestants,
             antihistamines, and herbal medication (including herbal tea and St. John's Wort)],
             within 14 days prior to study drug administration through the discharge visit, unless
             approved by the PI and Sponsor medical monitor. Occasional use of paracetamol at
             recommended doses is allowed. Special rules apply for aspirin, corticosteroids and
             nonsteroidal anti-inflammatory drugs (NSAIDS (see exclusion criteria 6-7-8-9)

          9. Venous access (both arms) sufficient to allow blood sampling and study drug
             administration as per protocol.

         10. Participants and their partners of childbearing potential [meaning who are not
             surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or
             post-menopausal (absence of menstrual periods for at least 12 consecutive months)]
             must be willing to use 2 methods of contraception: - a highly effective method of
             birth control starting at screening. Highly effective methods of birth control are
             defined as those that result in a low failure rate (i.e. Pearl Index less than 1% per
             year) when used consistently and correctly, such as implants, rings, patches,
             injectable or combined oral contraceptives, intrauterine devices (IUDs), or sexual
             abstinence (periodic abstinence e.g. calendar, ovulation, symptothermal, postovulation
             methods, declaration of abstinence for the duration of the trial, and withdrawal are
             not acceptable methods of contraception) . - and a local barrier form of
             contraception. Acceptable barrier methods are either the participant's use of a condom
             or the partner's use of an occlusive cap or diaphragm, or spermicides. Participants
             will not donate sperm from the selection visit and up to 90 days after the infusion.
             In case of sterile or vasectomised participants, no contraception will be required for
             their partners of childbearing potential.

         11. Willing/able to adhere to the study visit schedule and other requirements,
             prohibitions and restrictions specified in this protocol.

        Exclusion Criteria:

        If any of the following exclusion criteria apply, the participant must not enter the study:

          1. Currently have or have a history of any clinically significant medical illness or
             medical disorders the PI considers should exclude the participant, including (but not
             limited to) cardiovascular disease, neuromuscular, haematological disease, immune
             deficiency state, respiratory disease, hepatic or gastrointestinal disease,
             neurological or psychiatric disease, ophthalmological disorders, neoplastic disease,
             renal or urinary tract diseases, or dermatological disease.

          2. History of personal or familial bleeding disorders; including prolonged or unusual
             bleeding.

          3. History of deficiency in factor XII (FXII) or haemophilia type A (FVII) or type B
             (FIX) or type C (FXI).

          4. History of cerebral bleeding (e.g. after a car accident), stroke and cerebrovascular
             accident (CVA).

          5. Anamnestic history of Lyme disease or tick-borne encephalitis.

          6. Use of Acetylsalicylic-Acid (ASA)-containing OTC medications within 1 month prior to
             screening.

          7. Chronic administration of NSAIDs, chronic use of corticosteroids within 1 month prior
             to screening.

          8. Chronic administration of clopidogrel, ticlopidin, dipyridamole, Coumadin-like
             anticoagulants, new oral anticoagulant dabigatran, rivaroxaban, apixaban or edoxaban
             within 3 months prior to screening.

          9. Administration of unfractionated heparin, low molecular weight heparin, fibrinolytic
             agents and anti-FXa within 3 months prior to screening.

         10. Have an active acute or chronic infection or diagnosed latent infection.

         11. Systolic blood pressure (SBP) greater than 150 or less than 90 mmHg, diastolic blood
             pressure (DBP) greater than 90 or less than 50 mmHg, and heart rate (HR) greater than
             100 or less than 40 bpm.

         12. Acute clinically relevant illness within 7 days prior to study drug administration or
             have had a major illness or hospitalisation within 1 month prior to study drug
             administration.

         13. Major or traumatic surgery within 12 weeks of screening.

         14. Any participant who plans to undergo elective surgery within 4 weeks prior to study
             drug administration and through the discharge visit.

         15. Positive serology test for HIV antibodies, hepatitis B surface antigen (HBsAg), or
             hepatitis C virus (HCV) antibodies at screening.

         16. Recent history (within previous 6 months) of alcohol or drug abuse.

         17. Have positive urine toxicology screen at screening or D -1 for substances of abuse
             including amphetamines, benzodiazepine, cocaine, opiates, barbiturate and
             cannabinoids.

         18. Have a positive alcohol breath test at screening or D-1.

         19. Consumes, on average, more than approximately 500 mg/day of caffeine (as contained in
             5 cups of tea or coffee or 8 cans of caffeine-containing soda or other caffeinated
             products per day).

         20. Donated blood (i.e. 500 mL) within 3 months before D1.

         21. Have a history of active drug and/or food allergy or other active allergic disease
             requiring the constant use of medications, or a history of severe allergic reaction,
             angioedema or anaphylaxis.

         22. Received any other experimental therapy or new investigational drug within 30 days or
             5 half-lives (whichever is longer) of study drug administration.